Literature DB >> 18946752

Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version.

Toshirou Nishida1, Seiichi Hirota, Akio Yanagisawa, Yoshinori Sugino, Manabu Minami, Yoshitaka Yamamura, Yoshihide Otani, Yasuhiro Shimada, Fumiaki Takahashi, Tetsuro Kubota.   

Abstract

Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved greatly since the introduction of molecularly targeted therapies. Although several clinical practice guidelines are extant, such as those published by the National Comprehensive Cancer Network and the European Society of Medical Oncology, it is not clear as to whether these are appropriate for clinical practice in Japan. Therefore, clinical practice guidelines for the optimal diagnosis and treatment of GIST tailored for the Japanese situation have often been requested. For this reason, the Japanese Clinical Practice Guideline for GIST was proposed by the GIST Guideline Subcommittee, with the official approval of the Clinical Practice Guidelines Committee for Cancer of the Japan Society of Clinical Oncology (JSCO), and was published after assessment by the Guideline Evaluation Committee of JSCO. The GIST Guideline Subcommittee consists of members from JSCO, the Japanese Gastric Cancer Association (JGCA), and the Japanese Study Group on GIST, with the official approval of these organizations. The GIST Guideline Subcommittee is not influenced by any other organizations or third parties. Revision of the guideline may be done periodically, with the approval of the GIST Guideline Subcommittee, either every 3 years or when important new evidence that might alter the optimal diagnosis and treatment of GIST emerges. Here we present the English version of the Japanese Clinical Practice Guideline for GIST prepared by the GIST Guideline Subcommittee.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946752     DOI: 10.1007/s10147-008-0798-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  45 in total

1.  Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases.

Authors:  Yoshihide Otani; Toshiharu Furukawa; Masashi Yoshida; Yoshiro Saikawa; Norihito Wada; Masakazu Ueda; Tetsuro Kubota; Makio Mukai; Kaori Kameyama; Yoshinori Sugino; Koichiro Kumai; Masaki Kitajima
Journal:  Surgery       Date:  2006-04       Impact factor: 3.982

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection.

Authors:  Junichi Nishimura; Kiyokazu Nakajima; Takeshi Omori; Tsuyoshi Takahashi; Akiko Nishitani; Toshinori Ito; Toshirou Nishida
Journal:  Surg Endosc       Date:  2006-12-16       Impact factor: 4.584

4.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

5.  An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors.

Authors:  Tsuyoshi Takahashi; Kiyokazu Nakajima; Akiko Nishitani; Yoshihito Souma; Seiichi Hirota; Yoshiki Sawa; Toshirou Nishida
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.402

6.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

Review 8.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

9.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.

Authors:  Tadashi Hasegawa; Yoshihiro Matsuno; Tadakazu Shimoda; Setsuo Hirohashi
Journal:  Hum Pathol       Date:  2002-06       Impact factor: 3.466

10.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

Authors:  Harri Sihto; Maarit Sarlomo-Rikala; Olli Tynninen; Minna Tanner; Leif C Andersson; Kaarle Franssila; Nina N Nupponen; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  135 in total

1.  The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour.

Authors:  Kanae Kawai Miyake; Yuji Nakamoto; Yoshiki Mikami; Shiro Tanaka; Tatsuya Higashi; Eiji Tadamura; Tsuneo Saga; Shunsuke Minami; Kaori Togashi
Journal:  Eur Radiol       Date:  2016-02-06       Impact factor: 5.315

2.  Safe laparoscopic resection of a gastric gastrointestinal stromal tumor close to the esophagogastric junction.

Authors:  Yasuo Sakamoto; Yoshihisa Sakaguchi; Hisafumi Akimoto; Yoshiki Chinen; Miyako Kojo; Masahiko Sugiyama; Kazutoyo Morita; Hiroshi Saeki; Kazuhito Minami; Yuji Soejima; Yasushi Toh; Takeshi Okamura
Journal:  Surg Today       Date:  2012-01-24       Impact factor: 2.549

3.  Long-term outcomes of combined endoscopic/laparoscopic intragastric enucleation of presumed gastric stromal tumors.

Authors:  Jeffrey S Mino; Alfredo D Guerron; Rosebel Monteiro; Kevin El-Hayek; Jeffrey L Ponsky; Deepa T Patil; R Matthew Walsh
Journal:  Surg Endosc       Date:  2015-08-15       Impact factor: 4.584

4.  Totally laparoscopic resection of a very large gastric GIST.

Authors:  G Anania; L Dellachiesa; N Fabbri; L Scagliarini; G Ferrocci; A Pezzoli; G Resta
Journal:  G Chir       Date:  2013 Jul-Aug

Review 5.  Laparoscopic and endoscopic cooperative surgery for gastrointestinal tumor.

Authors:  Keiko Niimi; Rei Ishibashi; Takashi Mitsui; Susumu Aikou; Shinya Kodashima; Hiroharu Yamashita; Nobutake Yamamichi; Yoshihiro Hirata; Mitsuhiro Fujishiro; Yasuyuki Seto; Kazuhiko Koike
Journal:  Ann Transl Med       Date:  2017-04

Review 6.  Percutaneous endoscopic intragastric surgery: an organ preserving approach to submucosal tumors at esophagogastric junction.

Authors:  Eiji Kanehira; Aya Kamei Kanehira; Takashi Tanida; Kodai Takahashi; Kazunori Sasaki
Journal:  Transl Gastroenterol Hepatol       Date:  2017-05-16

7.  Technical success and short-term results of surgical treatment of gastrointestinal stromal tumors: an experience of three centers.

Authors:  Mark Igorevich Gluzman; Victor Anatolevich Kashchenko; Aleksei Mikhailovich Karachun; Rashida Vakhidovna Orlova; Iakov Aleksandrovich Nakatis; Iurii Vasilevich Pelipas; Evgenia Leonidovna Vasiukova; Ivan Vladimirovich Rykov; Veronika Vladimirovna Petrova; Svetlana Leonidovna Nepomniashchaia; Anton Sergeevich Klimov
Journal:  Transl Gastroenterol Hepatol       Date:  2017-06-02

8.  Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy.

Authors:  Yoshitomo Yanagimoto; Tsuyoshi Takahashi; Kazuya Muguruma; Takahiro Toyokawa; Hiroshi Kusanagi; Takeshi Omori; Toru Masuzawa; Koji Tanaka; Seiichi Hirota; Toshirou Nishida
Journal:  Gastric Cancer       Date:  2014-05-23       Impact factor: 7.370

9.  Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.

Authors:  Tatsuo Kanda; Takashi Ishikawa; Shin-Ichi Kosugi; Kyo Ueki; Tetsuya Naito; Toshifumi Wakai; Seiichi Hirota
Journal:  Int J Clin Oncol       Date:  2015-09-19       Impact factor: 3.402

10.  Predictors of unsuccessful laparoscopic resection of gastric submucosal neoplasms.

Authors:  Sabha Ganai; Vivek N Prachand; Mitchell C Posner; John C Alverdy; Eugene Choi; Mustafa Hussain; Irving Waxman; Marco G Patti; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2012-12-08       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.